Navigation Links
Barrier Therapeutics Announces Liarozole Phase 2/3 Study Results in,Lamellar Ichthyosis

Drug Effectively Treated 41 to 50% of Patients and Was Well-Tolerated
PRINCETON, NJ, Jun 14, 2007 (MARKET WIRE via COMTEX News Network) -- Barrier Therapeutics, Inc. (NASDAQ: BTRX), a pharmaceutical company that develops and markets dermatology products, today announced results from its completed Phase 2/3 study of liarozole in lamellar ichthyosis, a rare genetic disorder (incidence of approximately 1 in 200,000) which is characterized by a thick scaling of the skin over large body areas. Study results showed liarozole, dosed at 75 mg and 150 mg per day for 12 weeks, was well-tolerated and "effectively treated" the disorder in 41% and 50% of the patients, respectively. The primary efficacy endpoint, "effectively treated," was defined as the percentage of patients that obtained at least a 2 point reduction in investigator's global assessment (IGA) score as defined on a 5 point scale.

The randomized, double-blind, placebo-controlled dose ranging study enrolled 64 patients in three treatment groups. Patients received placebo, 75 mg or 150 mg of liarozole daily for 12 weeks, randomized 1:3:3, respectively. Response rates for the primary endpoint were 41% (11 of 27 patients) for the 75 mg dose, 50% (14 of 28 patients) for the 150 mg dose and 11% (1 of 9 patients) for placebo. The p-values for the 75 and 150 mg per day groups compared to placebo were p=0.2193 and p=0.0557, respectively.

For the secondary endpoints of mean IGA score at week 8 and the overall scaling score at weeks 8 and 12, both liarozole groups achieved statistically significant differences from placebo (p < 0.05). The mean IGA score at week 8 was reduced by 36% and 43% for the 75 and 150 mg liarozole treatment groups, respectively versus 3% for placebo. The mean IGA score for the two liarozole treatment groups continued to improve through 12 weeks. The mean reduction in overall scaling was approximately 45% for both liarozole treatment
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:5/23/2013)... , May 23, 2013  TeamHealth Medical Call ... triage and nurse advice lines, announces its newly ... physician, nursing and administrative leaders, provides clinical expertise ... and cost-effective services for hospital clients, physician clients ... healthcare system evolves, it,s imperative to continuously advance ...
(Date:5/23/2013)... SANTA MONICA, Calif. , May 23, 2013 /PRNewswire-USNewswire/ ... of a program that would have required them to ... announced today by Consumer Watchdog and Whatley Kallas LLC.  ... San Diego Superior Court, alleged that Blue Cross,s mandatory ... HIV/AIDS patients, threatening their health and privacy. ...
(Date:5/23/2013)... MILFORD, Mass. , May 23, 2013  Spring ... for the treatment of viral infections, today announced that ... of SB 9200, its investigational, once daily, oral therapy ... conducted in healthy, HCV-infected patients and is designed to ... 9200. SB 9200 is a first-in-class drug for the ...
Breaking Medicine Technology:TeamHealth Medical Call Center Forms Clinical Advisory Committee 2Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 2Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 3Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 2Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 3
... the region,s premier provider of diagnostic imaging services, is ... Hospital Council of Western Pennsylvania,s newest business partner. ... the expertise of a large, highly-skilled team of imaging ... area. By partnering with FRG, community hospitals are able ...
... OAKS, Calif., Oct. 18 Amgen (Nasdaq: ... Trial to Reduce Cardiovascular Events with Aranesp® Therapy) and ... of erythropoiesis-stimulating agents (ESAs) for chronic renal failure (CRF) ... Administration,s (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC). ...
Cached Medicine Technology:Hospital Council of Western Pennsylvania Announces Foundation Radiology Group as Newest Partner 2Amgen to Review Results From TREAT and Propose Updates to ESA Labeling for Chronic Renal Failure Patients at an FDA Advisory Committee Meeting Today 2Amgen to Review Results From TREAT and Propose Updates to ESA Labeling for Chronic Renal Failure Patients at an FDA Advisory Committee Meeting Today 3Amgen to Review Results From TREAT and Propose Updates to ESA Labeling for Chronic Renal Failure Patients at an FDA Advisory Committee Meeting Today 4Amgen to Review Results From TREAT and Propose Updates to ESA Labeling for Chronic Renal Failure Patients at an FDA Advisory Committee Meeting Today 5Amgen to Review Results From TREAT and Propose Updates to ESA Labeling for Chronic Renal Failure Patients at an FDA Advisory Committee Meeting Today 6Amgen to Review Results From TREAT and Propose Updates to ESA Labeling for Chronic Renal Failure Patients at an FDA Advisory Committee Meeting Today 7Amgen to Review Results From TREAT and Propose Updates to ESA Labeling for Chronic Renal Failure Patients at an FDA Advisory Committee Meeting Today 8
(Date:5/25/2013)... New York, New York (PRWEB) May 25, 2013 ... a federal multidistrict litigation underway in U.S. District Court, ... Liebhard LLP reports. According to a Case Management ... procedures that govern the filing of contested motions in ... for filing those motions. (In re: Actos Product Liability ...
(Date:5/25/2013)... May 25, 2013 Studies from Johns ... are carrying excessive weight and their inability to get ... simply losing weight can naturally relieve many symptoms. ... improvement in sleep quality was significantly associated with overall ... study dated November 6th, 2012, researchers monitored ...
(Date:5/25/2013)... York, NY (PRWEB) May 25, 2013 ... digestive problems, ranging from irritable bowel syndrome (IBS) ... problems are among the most long-lasting, embarrassing, frustrating ... natural foods for digestive health have ... While there are many factors contributing to digestive ...
(Date:5/25/2013)... UAE (PRWEB) May 25, 2013 Dr. ... LASIK surgery clinic in Dubai, has announced his practice’s ... laser is the only FDA-cleared femtosecond laser proven with ... the safety and precision of LASIK. , “We are ... iFS Advanced Femtosecond Laser at our Dubai LASIK practice,” ...
(Date:5/25/2013)... May 25, 2013 Prairie Living ... is hosting an American Red Cross Blood Drive from ... The community, which is located at 955 Villa Ct. ... including those on Medicaid, who need some help to ... of Life," says Andrea Arview Frey, Director of Marketing ...
Breaking Medicine News(10 mins):Health News:Actos Lawsuit News: Bernstein Liebhard LLP Notes New Case Management Order in Federal Actos Bladder Cancer Litigation 2Health News:Actos Lawsuit News: Bernstein Liebhard LLP Notes New Case Management Order in Federal Actos Bladder Cancer Litigation 3Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Offers Newly Improved hCG Diet Plans Capable of Delivering Better Sleep 2Health News:Natural Foods For Digestive Health Report and Video Published by BetterDigestion.org 2Health News:Atlanta Vision Clinic Acquires the Latest in Blade-Free Lasik Technology Bringing Dubai Patients the Intralase Method 2Health News:Carbondale Affordable Assisted Living Community to Host Red Cross Blood Drive 2
... , TUESDAY, Oct. 11 (HealthDay News) -- Environmental pollutants ... hardening of the arteries (atherosclerosis), according to a new ... cardiovascular diseases, which are the most common cause of ... University in Sweden. They measured levels of persistent ...
... have identified cells and signaling molecules that trigger the ... his colleagues report October 10, 2011, online in the ... lung tissue in mice induces smooth muscle cells surrounding ... growth factor 10 (FGF10), which induces surviving epithelial cells ...
... Reserve University School of Medicine and the Case ... receipt of a highly competitive $5.4 million grant ... esophageal adenocarcinoma. This five-year award from the National ... Research Network (BETRNet), which consists of multiple centers ...
... medications, including antidepressants, antihistamines, bronchodilators, anticholinergics, sympathomimetics, and ... tract symptoms among men according to a Kaiser ... Internal Medicine . This study demonstrates an ... drugs and LUTS among men enrolled in the ...
... Society for Radiation Oncology (ASTRO), the Association of Residents ... the 2011 Educator of the Year Award. , ARRO ... recognize outstanding teachers and mentors of radiation oncology residents. ... opportunity to select one faculty member from their program ...
... as herbal supplements have become increasingly popular in the ... chronic pain. However, many of these products can have ... medications prescribed during and after surgery, according to a ... American Academy of Orthopaedic Surgeons (JAAOS). , ...
Cached Medicine News:Health News:Environmental Toxins Linked to Hardening of Arteries 2Health News:Case Western Reserve receives prestigious $5.4 million grant to study esophageal cancer 2Health News:Case Western Reserve receives prestigious $5.4 million grant to study esophageal cancer 3Health News:Common medications can contribute to lower urinary tract symptoms in men 2Health News:ARRO honors 39 with Educator of the Year Award 2Health News:Herbal supplements may cause dangerous drug interactions in orthopaedic surgery patients 2Health News:Herbal supplements may cause dangerous drug interactions in orthopaedic surgery patients 3
... PDC Smart™ Labels have a direct ... Texas Instruments Tag-it™ HF-I transponder. When ... codes, text and other graphics may ... variable data is programmed to the ...
The PDC Smart® Key Fob can be programmed on demand using a 13.56 MHz RFID reader/writer and is ideal for long-term use applications such as electronic access control or loyalty programs....
... SURGICHIP™ is a patent pending ... technology embedded in a smart label ... to prevent wrong-patient, wrong-site, wrong-procedure surgery. ... developed by an orthopedic surgeon with ...
... are carefully crafted with the highest ... SATO Techno THERM RFID labels are ... optimum performance in your SATO printer ... are available in HF and UHF ...
Medicine Products: